Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion type Assertion NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_head.
- NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion wasGeneratedBy ECO_0000203 NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_provenance.
- NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion wasDerivedFrom befree-2016 NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_provenance.
- NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion SIO_000772 17091508 NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_provenance.
- NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion evidence source_evidence_literature NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_provenance.
- NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_provenance.